nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.04.2015 | Clinical Investigation

Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity

verfasst von: Toshihiro Iguchi, Takao Hiraki, Hideo Gobara, Hiroyasu Fujiwara, Yusuke Matsui, Junichi Soh, Shinichi Toyooka, Katsuyuki Kiura, Susumu Kanazawa

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We retrospectively evaluated the outcomes of lung cancer patients presenting with ground-glass opacity (GGO) who received radiofrequency ablation (RFA).

Methods

Sixteen patients (5 men and 11 women; mean age, 72.6 years) with 17 lung cancer lesions showing GGO (mean long axis diameter, 1.6 cm) underwent a total of 20 percutaneous computed tomography (CT) fluoroscopy-guided RFA sessions, including three repeated sessions for local progression. Lung cancer with GGO was defined as a histologically confirmed malignant pulmonary lesion with a GGO component accounting for >50 % of the lesion on high-resolution CT. Procedure outcomes were evaluated.

Results

There were no major complications. Pneumothorax occurred in 15 of 20 treatment sessions: 14 were asymptomatic, and 1 required chest tube placement but resolved satisfactorily within 48 h. Minor pulmonary hemorrhage occurred in two and mild pneumonitis in one. The median tumor follow-up period was 61.5 (range 6.1–96.6) months. The effectiveness rates of the primary and secondary techniques were 100 and 100 % at 1 year, 93.3 and 100 % at 2 years, and 78.3 and 92.3 % at 3 years, respectively. The median patient follow-up period was 65.6 (range 6.1–96.6) months. One patient died owing to recurrent other cancer 11.7 months after RFA, whereas the other 15 remained alive. Overall survival and disease-specific survival rates were 93.3 and 100 % at 1 year and 93.3 and 100 % at 5 years, respectively.

Conclusions

RFA for lung cancer with GGO was safe and effective, and resulted in promising survival rates.

Godoy MC, Naidich DP (2009) Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 253(3):606–622 PMID: 19952025CrossRefPubMed

Hiraki T, Sakurai J, Tsuda T et al (2006) Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer 107(12):2873–2880 PMID: 17096433CrossRefPubMed

Okuma T, Matsuoka T, Yamamoto A et al (2010) Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution. Cardiovasc Intervent Radiol 33(4):787–793 PMID: 19967367CrossRefPubMed

de Baère T, Palussière J, Aupérin A et al (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240(2):587–596 PMID: 16864679CrossRefPubMed

Lencioni R, Crocetti L, Cioni R et al (2008) Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9(7):621–628 PMID: 18565793CrossRefPubMed

Kim TJ, Lee JH, Lee CT et al (2008) Diagnostic accuracy of CT-guided core biopsy of ground-glass opacity pulmonary lesions. AJR Am J Roentgenol 190(1):234–239 PMID: 18094317CrossRefPubMed

Hur J, Lee HJ, Nam JE et al (2009) Diagnostic accuracy of CT fluoroscopy-guided needle aspiration biopsy of ground-glass opacity pulmonary lesions. AJR Am J Roentgenol 192(3):629–634 PMID: 19234257CrossRefPubMed

Hiraki T, Gobara H, Mimura H et al (2011) Percutaneous radiofrequency ablation of clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 142(1):24–30 PMID: 21529847

Hiraki T, Gobara H, Mimura H et al (2011) Radiofrequency ablation of lung cancer at Okayama University Hospital: a review of 10 years of experience. Acta Med Okayama 65(5):287–297 PMID: 22037265

10.

Yamamoto A, Nakamura K, Matsuoka T et al (2005) Radiofrequency ablation in a porcine lung model: correlation between CT and histopathologic findings. AJR Am J Roentgenol 185(5):1299–1306 PMID: 16247153CrossRefPubMed

11.

Abtin FG, Eradat J, Gutierrez AJ, Lee C, Fishbein MC, Suh RD (2012) Radiofrequency ablation of lung tumors: imaging features of the postablation zone. Radiographics 32(4):947–969 PMID: 22786987CrossRefPubMedCentralPubMed

12.

Hiraki T, Gobara H, Mimura H et al (2010) Does tumor type affect local control by radiofrequency ablation in the lungs? Eur J Radiol 74(1):136–141 PMID: 19231125CrossRefPubMed

13.

Goldberg SN, Grassi CJ, Cardella JF et al (2009) Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20(7 Suppl):S377–S390 PMID: 19560026CrossRefPubMed

14.

Noguchi M, Morikawa A, Kawasaki M et al (1995) Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75(12):2844–2852 PMID: 7773933CrossRefPubMed

15.

Kondo T, Yamada K, Noda K, Nakayama H, Kameda Y (2002) Radiologic-prognostic correlation in patients with small pulmonary adenocarcinomas. Lung Cancer 36(1):49–57 PMID: 11891033CrossRefPubMed

16.

Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A, Tsuchiya R (2003) A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. Ann Thorac Surg 76(4):1016–1022 PMID: 14529977CrossRefPubMed

17.

Nakao M, Yoshida J, Goto K et al (2012) Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol 7(10):1563–1566 PMID: 22878750CrossRefPubMed

18.

Hamamoto Y, Kataoka M, Yamashita M et al (2012) Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors. Jpn J Radiol 30(5):430–434 PMID: 22450903CrossRefPubMed

19.

Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243(1):268–275 PMID: 17392258CrossRefPubMed

20.

Ambrogi MC, Fanucchi O, Cioni R et al (2011) Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol 6(12):2044–2051 PMID: 22052222CrossRefPubMed

21.

Yasui K, Kanazawa S, Sano Y et al (2004) Thoracic tumors treated with CT-guided radiofrequency ablation: initial experience. Radiology 231(3):850–857 PMID: 15105453CrossRefPubMed

22.

Anderson EM, Lees WR, Gillams AR (2009) Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol 32(3):478–483 PMID: 19127381CrossRefPubMed

23.

Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195(3):758–765 PMID: 20729457CrossRefPubMed

24.

Kim KW, Lee JM, Klotz E et al (2011) Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol 196(5):W565–W572 PMID: 21512046CrossRefPubMed

25.

Hasegawa M, Sone S, Takashima S et al (2000) Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 73(876):1252–1259 PMID: 11205667CrossRefPubMed

26.

Kim TJ, Park CM, Goo JM, Lee KW (2012) Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol 198(1):83–88 PMID: 22194482CrossRefPubMed

27.

Kashima M, Yamakado K, Takaki H et al (2011) Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol 197(4):W576–W580 PMID: 21940529CrossRefPubMed

28.

Hiraki T, Mimura H, Gobara H et al (2008) Repeat radiofrequency ablation for local progression of lung tumors: does it have a role in local tumor control? J Vasc Interv Radiol 19(5):706–711 PMID: 18440459CrossRefPubMed

Titel: Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity
verfasst von: Toshihiro Iguchi
Takao Hiraki
Hideo Gobara
Hiroyasu Fujiwara
Yusuke Matsui
Junichi Soh
Shinichi Toyooka
Katsuyuki Kiura
Susumu Kanazawa
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 2/2015
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-014-0926-x

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity